Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The Asia Pacific Continuous Glucose Monitoring Systems (CGMS) Market is expected to grow at a CAGR of 32% during 2016 -2022. The inherent benefits of CGMS are far superior than self-monitoring blood glucose (SMBG) devices i.e., POC glucometers.
Also, the data obtained by CGMS and trend analysis is highly accurate and reliable as compared to other SMBG devicesPOC glucometers. Such unparalleled superiority would drive the market adoption much higher among the end-users. Increased and ongoing efforts of patient-education and screening for diabetes programs would increase awareness levels and eventually would drive the overall diabetes treatment and management market growth.
Significantly growing purchasing power among the end-user patient base in the developing and underdeveloped regions would act as a major factor driving the market during the forecast period. The report highlights the adoption of Continuous Glucose Monitoring Systems in Asia Pacific. Based on the Component, the Asia Pacific Continuous Glucose Monitoring Systems Market is segmented into Sensors, Transmitters & Receivers and Integrated Insulin pumps segment.
Based on the End user, the market is bifurcated into Diagnostic centersclinics, ICUs and Home Healthcare segments. The countries included in the report are China, Japan, India, South Korea, Singapore, Malaysia and Rest of Asia Pacific. Key Players profiled in the report includes Roche Diagnostics, Abbott Laboratories, Dexcom Inc., Novo Nordisk, Ypsomed AG, GlySens Incorporated, Medtronic Plc and Johnson & Johnson.